Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$40.91
+3.9%
$32.00
$16.53
$41.22
$1.12B0.42580,752 shs625,495 shs
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$47.70
-2.8%
$48.62
$26.70
$91.83
$1.03B2.62597,219 shs241,046 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$2.00
-6.1%
$1.75
$0.63
$2.60
$248.89M-0.57534,156 shs348,404 shs
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$11.13
$10.45
$2.86
$11.40
$992.13M2.233.94 million shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
+3.94%+27.37%+24.92%+52.59%+74.09%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-2.75%+0.91%-8.07%+28.85%-6.94%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-6.10%-4.31%+36.05%+47.06%+83.49%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
0.00%0.00%+1.00%+140.39%+152.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
1.1279 of 5 stars
2.61.00.00.03.10.80.0
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
1.8554 of 5 stars
3.41.00.00.02.91.70.0
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.6291 of 5 stars
0.03.00.00.02.51.70.0
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
2.9506 of 5 stars
4.24.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
3.17
Buy$49.6021.24% Upside
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.75
Moderate Buy$85.8880.03% Upside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
2.33
Hold$14.5730.92% Upside

Current Analyst Ratings Breakdown

Latest TLSA, VERV, LENZ, and PRAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$105.00 ➝ $115.00
7/31/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00 ➝ $49.00
7/31/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$39.00 ➝ $40.00
7/29/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
7/28/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $48.00
7/18/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$105.00
7/8/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$97.00 ➝ $115.00
6/27/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.50
6/26/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/18/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$28.00 ➝ $11.00
6/18/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$12.00
(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/A$7.24 per shareN/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$8.55M117.44N/AN/A$19.21 per share2.48
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.04 per shareN/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$32.33M30.69N/AN/A$5.83 per share1.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%N/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$182.82M-$12.29N/AN/AN/A-2,137.48%-60.07%-54.84%N/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$11.86MN/A0.00N/AN/AN/AN/A10/13/2025 (Estimated)
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/A

Latest TLSA, VERV, LENZ, and PRAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025 & Study Result
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$3.40-$3.31+$0.09-$3.31$0.15 millionN/A
7/30/2025Q2 2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/AN/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/A
20.54
20.54
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/A
6.31
6.31
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
1.02
1.02
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/A
9.84
9.84

Institutional Ownership

CompanyInstitutional Ownership
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
54.32%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
67.84%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
97.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
11028.52 million26.55 millionN/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
11021.05 million20.48 millionOptionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million70.32 millionOptionable
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
11089.14 million71.94 millionOptionable

Recent News About These Companies

Verve Therapeutics Announces Merger and Nasdaq Delisting
Biotech lab
3 Bullish Biotech Stocks With Explosive Growth Trends
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
LENZ Therapeutics stock logo

LENZ Therapeutics NASDAQ:LENZ

$40.91 +1.55 (+3.94%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$41.40 +0.49 (+1.20%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Praxis Precision Medicines stock logo

Praxis Precision Medicines NASDAQ:PRAX

$47.70 -1.35 (-2.75%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$47.74 +0.03 (+0.07%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$2.00 -0.13 (-6.10%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$2.09 +0.09 (+4.55%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Verve Therapeutics stock logo

Verve Therapeutics NASDAQ:VERV

$11.13 0.00 (0.00%)
As of 07/25/2025

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.